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PROFORMA 
EFFECTS OF LONGTERM ANTIEPILEPTIC DRUGS ON VASCULAR 
RISK FACTORS AND ATHEROSCLEROSIS 
 
PATIENT INFORMATION: 
SERIAL NO. 
 
NAME:                                                              AGE ……. YEARS         
GENDER:   MALE/FEMALE                          MIN NO.                           
OP NO:   
 HEIGHT:              cm                                      WEIGHT:     kg          BMI- 
 
ADDRESS:                                                    PHONE NO 
Age of onset of epilepsy: 
Duration of epilepsy: 
Duration of AED: 
Dosage of AED in mg/day 
Average seizure frequency per month during previous 1 year; 
HISTORY & PRESENTATION: 
SEIZURE: 
Description of ictus; 
Post ictal state 
  
TYPE OF SEIZURE: 
1.Primary generalized(GTCS) 
2.Focal with secondary generalization 
3.complex partial 
4.Absence  
5.Myoclonic jerks 
6.others 
Average no. of seizure ………..over……..(day/week/month/year) 
Idiopathic / Cryptogenic 
Symptomatic : 
Cluster attacks 
Status epilepticus 
Fever /Headache/Vomiting/ 
Limb Weakness 
Sensory disturbance 
Altered behavior 
Trauma  
Others: 
PAST HISTORY: 
Type of seizure-GTCS/simple/complex/absence/Myoclonus 
Frequency……per………. 
Number of years in remission(before current presentation)………yrs 
Type of AED used in past – 
1.PHT   2.PB   3.CBZ  4.Valproate      5.oxycarbamazepine     6.Others 
Febrile seizure in childhood 
Simple febrile/ Complex febrile seizure 
ASSOCIATED CONDITIONS: 
TIA/ CVA 
Head injury 
Surgery 
Meningoencephalitis 
 Congnitive decline       
COMORBIDITIES 
DM  /  Hypertension / CAD /Stroke / Hyperlipidemia     /Liver disease  / 
Kidney disease 
Rheumatological illness 
Medications for systemic illnesses(with duration) 
PERSONAL HISTORY 
Alcoholism     /smoking /tobacco chewing / 
Diet      Vegetarian  / Non vegetarian 
FAMILY HISTORY 
Seizure   /DM /HT / CAD /Hyperlipidemia 
Others 
EXAMINATION: 
Temperature          Pulse          BP         mmHg           pallor 
Icterus                Lymphadenopathy                 Clubbing              Pedal oedema 
Carotid bruit                                  Peripheral pulsation         
Thyroid swelling 
Neurocutaneous markers 
CVS: 
RS:                                                     ABDOMEN: 
CENTRAL NERVOUS SYSTEM: 
Sensorium:GCS  :  E      V         M 
Meningeal signs: 
HMF; 
Cranial nerves: 
Spino motor system: 
CEREBELLAR Signs 
Sensory: 
0thers 
LAB INVESTIGATIONS 
Hb %     gm% 
TC 
DC 
ESR 
Blood sugar 
Blood urea 
Serum creatinine 
Electrolytes: 
X ray CHEST 
USG ABDOMEN 
THYROID PROFILE: 
 
CSF: 
ECG 
ECHO 
EEG- 
 FASTING LIPID PROFILE 
Total Cholesterol 
LDL- C 
HDL- C 
Triglycerides 
CRP: 
CT BRAIN: 
 
MRI BRAIN: 
 
COMMON CAROTID INTIMA MEDIA THICKNESS(CCA-IMT) 
RIGHT CCA IMT – 
LEFT  CCA  IMT – 
AVERAGE CCA  IMT - 
 
AEDs  DETAILS: 
 
 
 
DIAGNOSIS: 
 
 
ABBREVIATIONS 
AED   - Antiepileptic drug 
BMI    – Body mass index 
 CBZ   - Carbamazepine 
CCA    – Common carotid artery 
CVD    - Cardiovascular disease 
 CSWSS   - Continuous spike and wave in slow wave 
     sleep 
CHD    - Coronary heart disease 
CNS   - Central nervous system 
CIMT   - Carotid intima media wall thickness 
 CRP    - C-reactive protein  
EEG    - Electroencephalography 
GTCS   – Generalised tonic clonic seizure 
 HDL- C  - High-density lipoprotein cholesterol 
LDL-C   - Low-density lipoprotein cholesterol 
MI    – Myocardial infarction 
 PB    - Phenobarbitone 
 PHT    - Phenytoin 
PRM    - Primidone 
 ROS    - Reactive oxygen species 
 TC   - Total cholesterol 
TGL    - Triglyceride 
 VPA    - Valproic acid 
 VSMCs   - Vascular smooth muscle cells 
 WHO   - World Health Organization 
 
 
  
 
 
  
 
 
  
 
 
 TURNITIN-PLAGIARISM SCREEN SHOT 
 
 
 
 
 
 
 
 
 
 
 
 
  
TURNITIN-DIITAL  RECEIPT 
 
1 
 
INTRODUCTION 
Epilepsy is one of the most common disorders of the brain.
1
 One of 
every ten people will have at least one epileptic seizure during a normal 
lifespan  and a third of these will develop epilepsy. 50 million people  are  
affected by epilepsy worldwide, accounting for 1% of the global burden 
of disease, equivalent to lung cancer in men and breast cancer in women.
2 
  More than 30% of epileptic patients have to undergo longterm 
therapy with antiepileptic drugs.
3
 Prolonged AED therapy is  associated 
with several adverse effects such as metabolic disturbances, idiosyncratic 
reactions, behavioral or psychiatric problems and drug interactions.
4 
 
Risk factors for atherosclerotic events and cardiovascular disease 
include male sex, increased age, elevated plasma total cholesterol (TC), 
low-density lipoprotein cholesterol (LDL-C), decreased high-density 
lipoprotein cholesterol (HDL-C), CRP, high blood pressure, smoking and 
diabetes mellitus.
5-7
 
 
Annegers et al
8
 in their study have reported a high death rate due to 
ischemic heart disease and sudden cardiac death in symptomatic epileptic 
patients. But however a clarity on the issue of AED intake leading to 
cardiovascular mortality is not very clear. In this context there have been 
2 
 
few studies that have indicated that long term AED intake has been 
associated with increased vascular risk factors.  
           
   With this background the study of long term effects of 
antiepileptic drugs on vascular risk factors and atherosclerosis was 
conducted.  
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AIMS OF THE STUDY 
 
 
 
1. To study the effect of antiepileptic drugs on vascular risk factors 
namely serum Lipid profile and CRP in epileptic patients.  
 
2. To assess the effect of antiepileptic drugs on carotid intima media 
thickness, a marker of atherosclerosis in epileptic patients. 
 
3. To assess the correlation between duration of the antiepileptic 
drugs, and carotid intima media thickness. 
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REVIEW OF LITERATURE 
   
An epileptic seizure is a clinical event, which result from the 
synchronous and excessive discharge of a group of neurons in the 
cerebral cortex. 
Epilepsy is the tendency to have recurrent, unprovoked seizures. 
Seizures can result from specific precipitants such as fever in young 
children; soon after stroke; metabolic disturbances. These seizures are 
termed acute symptomatic seizures. Following such seizures, the chance 
of an unprovoked seizure is usually quite low and so the person would 
not be considered as having epilepsy. 
By this definition the incidence of epilepsy is 0.3–0.5% in different 
populations throughout the world, and the prevalence of epilepsy has 
been estimated at 5–10 persons per 1000.9 
 The classification of epilepsy: 
While epilepsy is best considered a symptom of an underlying 
brain disorder, we can classify someone’s epilepsy by aetiology, but this 
tells us very little about the clinical expression of the seizures, about the 
prognosis and about the expected findings on EEG. This information is 
contained within the classification of seizures and  epilepsy. There is an 
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accepted international classification of seizures and epilepsy that is at 
present under revision. However, the basic concepts will be preserved.  
The present International League against Epilepsy classification  
has a number of limitations, that it does not account for recent advances 
in genetics and neuroimaging. 
Classification of seizures 
The clinical manifestation of a seizure depends upon where in the 
brain it starts, and how far and fast it spreads. Seizures are divided into 
two broad categories: those originating from a localised cortical area are 
classified as partial (focal) seizures, and those characterized by initial 
synchronous discharges over both hemispheres are classified as 
generalised seizures.  
Partial (focal) seizures 
Sixty percent of focal seizures begins in the temporal lobes , with 
the remainder begins in the frontal lobes. Seizures originating in the 
parietal or occipital regions are relatively rare. Partial seizures are 
classified into three groups: simple partial, complex partial, and partial 
with secondary generalisation. Simple partial seizures are focal seizures 
in which consciousness is fully preserved. They are usually brief, 
stereotypical and intense, and their manifestation depends upon where the 
seizure begins. Common symptoms in temporal lobe epilepsy include: 
6 
 
d´ej`a vu, ‘butterflies’, fear, illusions and hallucinations (auditory, 
olfactory and gustatory) and complex visual hallucinations. In frontal 
lobe epilepsies, there can be focal jerking that can spread as a ‘Jacksonian 
March’, more complex motor posturing, a difficult-to-describe feeling in 
the head, and forced thinking. In occipital lobe epilepsy, there can be 
simple visual hallucination, usually coloured blobs in one part of the 
visual field. With parietal lobe epilepsies there can be focal sensory 
phenomena such as tingling that is sometimes painful, somatic illusions 
such as distortion of mouth or limb, or even sensations of vertigo.  
Complex partial seizures are partial seizures with impaired  
consciousness. They can start as a simple partial seizure  or the person 
may have impaired consciousness from the onset of seizure. In temporal 
lobe epilepsy, there may be motor arrest followed typically by chewing, 
lip smacking and swallowing (oroalimentary automatisms), and then 
fiddling with the hands (limb automatisms). Frontal lobe epilepsies can 
have more complex movements associated with them such as odd 
posturing (‘fencing posture’), large gestural movements such as pushing 
away, or rocking, as well as running, scissoring or cycling movements of 
the legs.  
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Generalised seizures: 
The commonest of these are the tonic–clonic seizure and absence 
seizures, but there are also rarer seizure types. Generalised tonic–clonic 
seizures (GTCS; often termed convulsions) usually occur without 
warning, although sometimes they can be preceded by increasing 
frequency of another generalised seizure type, such as myoclonic jerks or 
absences. Initially the person is tonic (stiff) and may cry out (the 
‘epileptic cry’). The person will fall and may bite the side of the tongue 
as the jaw clenches. The person may also become cyanosed at this point. 
Clonic movements then begin, usually predominantly in the upper limbs. 
These are coordinated regular jerks that eventually slow and stop, at 
which point incontinence can occur. Most convulsions last less than 2 
minutes. There is then a post-ictal period characterized by sleepiness and 
confusion lasting up to 20 minutes, but it may take longer for people to 
get over the full effects of the seizure (including lethargy, muscle aches, 
headache and a severely bitten tongue). 
Typical absence seizures almost always begin in childhood or 
adolescence. There is motor arrest and staring. On occasions there can be 
fluttering of the eyelids, swallowing, and flopping of the head. The 
attacks usually last a few seconds, can  occur many times a day and may 
be unrecognized, leading to a delay in diagnosis. There is immediate 
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recovery and no post-ictal phase. This seizure type is associated with a 
characteristic EEG of three-per-second generalized spike-and wave 
discharges. There are also atypical absences, which are usually part of 
more severe epilepsy syndromes associated with learning difficulties, 
such as the Lennox–Gastaut syndrome. In these the EEG is different, with 
slower and more irregular spike-and-wave discharges. Also the onset and 
cessation of the seizure is less clear and there are often additional features 
such as changes in body tone. Myoclonic seizures are sudden jerks that 
can involve a part of or the whole body.  
They commonly occur in the morning within a couple of hours of 
waking in idiopathic generalised epilepsies  Although they usually occur 
in more benign epilepsy syndromes, they can rarely be associated with 
devastating epilepsies with cognitive and neurological decline – the 
progressive myoclonic epilepsies. Not all myoclonus is epileptic and can 
even be physiological, for example sleep starts (hypnic jerks). Other 
generalised seizures consist of mainly atonic and tonic seizures. These are 
often termed ‘drop attacks’ and consist of sudden loss of body tone 
(atonic) or sudden increase in body tone (tonic), resulting in a fall. 
Recovery is generally rapid, notwithstanding any head injury.
10
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Classification of epilepsy syndromes 
An epilepsy syndrome consists of a combination of clinical, seizure 
and EEG characteristics that make up a distinct entity. Diagnosis of an 
epilepsy syndrome has implications for prognosis and management. 
However, diagnosis of a particular epilepsy syndrome does not 
necessarily imply a single aetiology: many epilepsy syndromes are 
known to have multiple aetiologies. Some epilepsy syndromes are 
characterised by generalized seizures, others by focal seizures, and a few 
by both focal and generalised seizures. The first two of these can be 
considered generalised and focal epilepsy syndromes, respectively. Some 
epilepsy syndromes are always or nearly always idiopathic; others are 
always or nearly always symptomatic or probably symptomatic, but a 
number exist in idiopathic, probably symptomatic and symptomatic forms 
(e.g. West syndrome). 
The term epileptic encephalopathy is used to denote epilepsies in 
which ongoing epileptic activity gives rise to progressive but potentially 
reversible neurological dysfunction which can be manifested as learning 
and behavioural problems or occasionally as motor problems. Only a very 
small number of epilepsies follow this pattern. 
10 
 
Febrile seizures 
Febrile seizures are the commonest type of epileptic seizure 
occurring in 2–5% of the general population. They are epileptic seizures 
occurring in association with fever but without evidence of infection of 
the CNS, excluding those who have had previous non-febrile seizures or 
in whom there is a known cause of seizures. They usually occur between 
the ages of six months and six years. A family history is common. Most 
febrile seizures are GTCS, but other seizure types can be precipitated by 
fever, including tonic, clonic and myoclonic seizures. It is usual to 
classify febrile seizure as simple or complex.  
Idiopathic generalised epilepsies 
These are common forms of epilepsy occurring in childhood, 
adolescence and in adult life, and feature combinations of three seizure 
types: typical absences, myoclonic seizures and GTCS. In all of them a 
family history of epilepsy and of febrile seizures in infancy/early 
childhood is common.  
EEG shows generalised discharges of spike and wave or of 
spikes/multiple spikes, the latter being characteristic of syndromes with 
myoclonic seizures. Despite reports of linkage to a variety of 
chromosome regions and of specific mutations in individuals and 
families, their genetic basis is still unclear. 
11 
 
Childhood absence epilepsy is common in 4years to 9 years of 
age group, girls are more affected than boys. It is characterised by typical 
absence seizures, usually lasting less than 20 seconds and occurring many 
times each day. The EEG is characterised by generalised 3-Hz spike-and-
wave discharges. Response to appropriate medication is usually excellent, 
and most children become seizure free. The epilepsy commonly resolves, 
usually before age 12 years.  
Juvenile absence epilepsy is similar to childhood absence 
epilepsy, but is rarer and usually starts in later childhood or adolescence. 
The typical absence seizures occur less frequently, but GTCS are 
common and occasional myoclonic jerks may also occur. Response to 
appropriate treatment is generally good, but the condition is likely to 
persist throughout adolescence and into adult life. 
Juvenile myoclonic epilepsy is also common and probably under 
diagnosed. It usually begins between the ages of 10 and 18 years and has 
a genetic basis.  
The epilepsy consists of early morning and/or late-evening 
myoclonic jerks, tonic–clonic seizures (in most) and absences (in a third).  
the condition is usually lifelong. 
Benign myoclonic epilepsy of infancy is rare, usually starting 
between six months and three years of age. The predominant, often sole, 
12 
 
seizure type is myoclonic seizures occurring singly or inclusters. They 
may arise spontaneously or be provoked by noise or tactile stimuli.  
Doose syndrome have myoclonic–astatic seizures; this starts in 
early childhood and is characterised by drop attacks caused by myoclonic 
seizures, atonic seizures (seizures characterized by a loss of muscle tone) 
or a combination of these seizure types (myoatonic seizures), and 
photically induced eyelid myoclonia with absences.  
Benign childhood epilepsy with centro-temporal spikes, which 
is also known as benign Rolandic epilepsy, usually starts in mid to late 
childhood and is probably the commonest type of new-onset epilepsy in 
otherwise normal children in this age group. The seizures are focal and 
characterised by tingling and numbness of the lips and tongue, and 
twitching at the corner of the mouth. Seizures may spread, leading to 
impairment of consciousness and/or hemiclonic or GTCS. A majority of 
seizures occur in sleep, during which spread may be very rapid, such that 
the initial focal onset is not apparent. The EEG characteristically shows 
so-called centro-temporal spikes. Seizure remission is expected within a 
few years, and certainly before the age of 16 years. 
Panayiotopoulos syndrome is also common, usually occurring in 
children of about four to six years of age. The seizures are characterized 
by autonomic symptoms, particularly nausea, retching and vomiting, 
13 
 
which usually begin in clear consciousness. Most seizures, however, 
progress with impairment of consciousness and sometimes hemiclonic 
and/or GTCS. Some seizures are mainly characterised by the child 
becoming flaccid and unresponsive. Characteristically the seizures are 
prolonged, often lasting over 30 minutes. A majority of the seizures occur 
in sleep and are very liable to be misdiagnosed. The EEG is characterised 
by multifocal spike-and-wave abnormalities. Total seizure count is 
usually low and remission is expected within a few years of onset. 
EPILEPTIC ENCEPHALOPATHY: 
West syndrome usually begins in the first year of life (peaking at 
three to nine months). The typical seizures are called epileptic or infantile 
spasms and consist of brief (up to a few seconds) episodes of contraction 
of truncal and limb uscles causing extension or flexion of the trunk and 
flexion or extension of the limbs. They may be quite subtle, particularly 
at onset. The seizures often occur in clusters, soon after awakening, on 
defecation or on feeding.  
The EEG usually shows a characteristic pattern termed 
hypsarrhythmia. An identifiable cause can be found in around 90% of 
patients.  
14 
 
Structural brain abnormalities are common and can be genetic or 
acquired in origin. Tuberous sclerosis is the single commonest cause of 
West syndrome. 
Some chromosomal abnormalities, including Down syndrome, are 
associated with a greatly increased risk of West syndrome. Occasionally 
West syndrome arises as a consequence of metabolic disorders, which 
may require specific treatments. Many children with West syndrome have 
developmental delay prior to onset of seizures. The onset of seizures is 
usually marked by developmental slowing, stagnation or regression, 
andmanychildren with the disorder will ultimately be diagnosed with 
severe learning difficulties. Up to20% eventually function within the 
normal range. This is more likely to be the case in those with idiopathic 
West syndrome. Epileptic spasms often subside after weeks, months or 
years. Some children remain seizure free but others develop other forms 
of epilepsy, including the Lennox–Gastaut syndrome.  
Lennox–Gastaut syndrome is a rare epilepsy usually beginning in 
early–mid childhood and characterised by frequent seizures of multiple 
types including tonic and atonic seizures and atypical absences. Tonic–
clonic, myoclonic and focal seizures may also occur.  
15 
 
Dravet syndrome  usually begins after six months of life in a child 
who has been developing normally. Onset is typically with a febrile 
seizure, often prolonged with focal features, and may follow vaccination.  
Further similar seizures are likely over the next few months, some clearly 
febrile (but often low-grade fever), others during intercurrent illness 
without definite fever.  
Usually in the second or occasionally third year of life the picture 
changes, with multiple seizure types developing. These may include 
myoclonic seizures, atypical absences, GTCS and focal seizures. Seizures 
often continue to be precipitated by fever and intercurrent illnesses. 
Accompanying the onset of this polymorphous epilepsy, developmental 
stagnation and even regression occurs and all affected children will 
eventually have severe learning difficulties, often with autistic 
behavioural problems. Motor problems, such as ataxia and spasticity, 
commonly develop. Eventually, often after some years, seizure frequency 
tends to reduce. The EEG is not particularly useful in the diagnosis, 
usually being normal early on. However, early photosensitivity is seen in 
a minority. Doose syndrome sometimes behaves as an epileptic 
encephalopathy, with around a half of those affected developing learning 
difficulties.  
16 
 
The Landau–Kleffner syndrome is a rare disorder usually 
occurring in previously normal children. It is characterised by a rather 
non-specific epilepsy (often mild) accompanied by regression in language 
and marked behavioural problems. Children developing it are often 
suspected of being deaf. It is usually accompanied by a characteristic 
EEG abnormality known as continuous spike and wave in slow wave 
sleep (CSWSS).   
Similar problems can arise in children with other forms of epilepsy, 
with or without structural brain abnormalities, sometimes precipitated by 
AED medication. 
Symptomatic/cryptogenic focal epilepsies 
The symptomatic/cryptogenic focal epilepsies can occur at any age, 
and the seizure manifestation depends upon where in the cortex the 
seizure begins and how far and fast the seizure spreads. 
Atherosclerosis: 
Epidemiology of Coronary Heart Disease: 
 
Cardiovascular disease (CVD) is the most frequent cause of 
premature death in  both developed and in developing countries. The 
common form of CVD are  stroke and coronary heart disease (CHD). 
17 
 
Risk Factors for Atherosclerosis: 
Around one third of CHD and ischemic stroke in developed 
countries is related to increased body mass index ( BMI ) levels.
13 
Risk of 
CHD is also directly related to blood cholesterol levels. Around 50% of 
CHD and ischemic stroke in developed countries is due to elevated  total 
blood cholesterol levels.  
Atherosclerosis 
Atherosclerosis is a focal, inflammatory fibro proliferative 
response to endothelial injury. Russell Ross and colleagues proposed 
endothelial injury hypothesis 30 years ago.
14
 
The normal artery wall is composed of two organized layers: 
intima and media. The intima is made up of a single layer of endothelial 
cells that are seated on basement membrane and then the internal elastic 
lamina . Beneath the IEL is the medial layer, comprising vascular smooth 
muscle cells (VSMCs) surrounded by basement membrane and embedded 
in interstitial extracellular matrix. The boundary of the media is marked 
by the external elastic lamina (EEL).  
All infants have focal thickening of the coronary artery intima due 
to VSMC proliferation.
15
 Although focal thickening is an important 
hallmark of the developing atherosclerotic plaque, this is considered to be 
an adaptive response to turbulent blood flow rather than pathological.  
18 
 
Endothelial dysfunction initiated by the risk factors already 
described permits the entry of lipids and inflammatory cells into the 
artery wall. Once in the artery, monocytes differentiate into macrophages 
which take up the lipid and become foam cell macrophages. This results 
in the formation of lesions termed “fatty streaks,” recognized as the onset 
of atherosclerosis  Fatty streaks are small, slightly raised lesions caused 
by focal collections of foam cell macrophages in the intima. They may be 
precursors of larger atherosclerotic plaques, but may also regress. 
Progression of the fatty streak to a more complex lesion occurs due to the 
formation of a necrotic core and a fibrous cap  Foam cell macrophages, 
engorged with lipid, begin to die and release their contents, which 
contributes to the formation of a necrotic core. The release of the 
cytoplasmic contents of the foam cells leads to the accumulation of 
extracellular lipids and growth factors which induce infl ammation. The 
occurrence of VSMC migration and proliferation results in the formation 
of a fi brous cap. VSMCs migrate into the intima where they proliferate 
and deposit extracellular matrix. Stable advanced plaque is formed due to 
increased number of cells and matrix. The size and composition of the 
plaque determine its outcome. 
19 
 
Classification schemes have been devised to categorize the various 
plaque types.
16-19 
1. unstable plaque 
2.stable plaque
 
   Rupture of the plaque cause thrombus formation.However, plaque 
rupture does not always lead to occlusion of the artery and the plaque 
may restabilize and heal over.
20
 This is at a cost since the “ healed 
plaque” is larger and repeated episodes of plaque rupture and healing is 
associated with a greater incidence of a fatal event.
21 
 
20 
 
Stages of atherosclerotic plaque formation : 
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EFFECT OF C-REACTIVE PROTEIN ON ATHEROSCLEROSIS: 
Raised C-reactive protein (CRP) is a marker of systemic 
inflammation, which predicts cardiovascular events such as stroke and 
myocardial infarction among apparently healthy individuals.
13
 Moreover 
elevated CRP levels are associated with an increase risk of recurrent 
infarction or death.
22
 The grade of immunoreactivity of CRP ha been 
found to be positively correlated with the size of coronary plaques, as 
well as the coronary intima media wall thickness (IMT). 
Recently, Zhang et al.
23
 demonstrated the existence of CRP in human 
coronary arteries and observed a positive correlation between increased 
coronary IMT and the grade of CRP immunoreactivity 
 
EPILEPSY AND VASCULAR DISEASE: 
Epidemiology : 
Several studies demonstrated positive correlations between 
epilepsy and vascular disease.Mortality ratio  due to ischemic heart 
disease in epilepsy patients is 1.2 to 2.5.
8,24
 An  Mortality ratio  of 10.7 
reported in a chinese study on death certificates  due to  myocardial 
infarction ,
25
 and  myocardial ischemia  was positively correlated with 
epilepsy.
26
 30% to 60% of epileptic patients showed significantly  
increased milder form of  ischemic heart disease.
8,27 
A Stronger 
24 
 
correlations between cerebrovascular disease and epilepsy was seen, with 
morbidity of 7 and mortality ratios of 3.7 to 5.3
24
 in one study.
27 
A low prevalence of ischemic heart disease and  29% lower 
mortality due to heart disease who were on enzyme-inducing AEDs  was 
seen in a Finnish study.
28
 It is possible that this could be due to genetic 
variants in Finnish population.no significant differences in coronary risk 
factors was found between epileptic patients and controls in  a Norwegian 
study.
29
  
Enzyme induction effects of AEDs on cholestrol: 
The enzyme-inducing AEDs carbamazepine(CBZ), phenytoin 
(PHT), primidone (PRM) and phenobarbital (PB), induces the  
cytochrome P450 system which play a role in the  synthesis of  
cholesterol. 
 In the synthesis of cholesterol pathway CYP51A1 
enzyme,catalyzes the  reaction of convertion of lanosterol to cholesterol 
intermediates
30
 which are further metabolished. When  there is inhibition 
of the enzyme  which metabolise these cholesterol intermediates,  these 
intermediates increase Which in turn inhibit the rate-limiting step of 
cholesterol synthesis, 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
and slow the synthesis of cholesterol  this is shown in a animal model but 
not studied extensively in human.
31
 According to this,  induction of 
25 
 
CYP51A enzyme  increase metabolism of these cholesterol intermediates 
and reduced feedback inhibition.thereby increasing cholesterol synthesis. 
An enzyme-inducing AED such as CBZ,PHT,PB should raise serum 
cholesterol whereas valproic acid (VPA), an enzyme-inhibiting drug, 
should reduce the production of cholesterol. 
 
Enzyme-inducing AEDs and lipid levels: 
 
Studies have shown that the enzyme inducers CBZ, PB, PHT, and 
PRM can lead to increased serum cholesterol levels. Significant Elevation 
of total cholesterol and lowdensity lipoprotein (LDL) cholesterol were 
found with CBZ use in various studies.
32-40
 
      Very less studies are available in PHT, with some studies showing 
nonsignificant increase in total cholesterol along with increased high-
density lipoprotein cholesterol (HDL-C).
42,43
 There is only one study  
which shows significant elevations in total cholesterol demonstrated and 
low density lipoprotein (LDL) cholesterol.
44
 PB also found to been 
associated with increased total cholesterol and LDL-C in children
45
 and 
adults.
40
 In a single study Primidone, was associated with higher total 
cholesterol and HDL-C  as well as total cholesterol/HDL-C ratios in 
children with epilepsy.
46
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      Thus, enzyme-inducing AEDs increase total cholesterol in many 
studies as would be expected by the enzyme induction hypothesis. There 
is a study, in which enzyme-inducing AEDs CBZ and PHT users who 
were switched to the non-enzyme-inducing agents lamotrigine or 
levetiracetam had significant decreases in total cholesterol and LDL-C 
levels.
44
 which Support the enzyme induction hypothesis. There is 
another study in which patients on CBZ who were switched to 
oxcarbazepine a weak enzyme-inducer had decreased total serum 
cholesterol.
47
 VPA is associated with lower serum LDL and/or total 
cholesterol in children and adults in many studies 
34,36,37,40,43,48 
Effects of AEDs on C-reactive protein: 
C-reactive protein (CRP), is an inflammatory marker and also a 
marker of vascular disease. The normal range for CRP is <6mg/l. 
Baseline CRP levelsis an independent vascular risk markers for 
cardiovascular disease.
49-52 
CRP was elevated in patients on mixed AEDs, 
compared to  controls.
52
 There was a significant reduction of CRP, when 
patients on enzyme-inducing AEDs were changed to nonenzyme-
inducing agents.
44
 The mechanism by which enzyme-inducing AEDs 
increases CRP is not known. 
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Effects of AEDs on carotid intima-media thickness: 
It is still not clear whether increase in vascular risk factors by 
enzyme-inducing AEDs results in increased incidence of ischemic events. 
Carotid intima-media thickness is a marker of atherosclerosis and its 
increase is significantly associated with major vascular events as 
established in many studies.
53-55
 According to a study
56
 patients treated 
with enzyme-inducing AEDs showed increased Carotid intima-media 
thickness when compared to controls. In another study patients who have 
taken CBZ showed increased Carotid intima-media thickness than 
patients on valproate, whereas patients on VPA had increased  Carotid 
intima-media thickness than untreated epileptic patients.
57
In pediatric 
epileptic patients VPA increases Carotid intima-media thickness without 
increasing lipid profile.
58
There is positive correlation between duration of 
AEDs and Carotid intima-media thickness.
52 
The above studies established that enzyme-inducing AEDs is 
significantly associated with vascular risk factors. The mechanism by 
which VPA alters vascular risk factors is not still clear.
 
Adverse Effects of Antiepileptic Drugs: 
 Treatment failure occurs  due to Adverse effects of antiepileptic 
drugs (AEDs)  in upto 40% of epileptic patients . These adverse effects 
can have a considerable impact on quality of life. 
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There are  five types of  adverse effects of AEDs 
Type A is a acute one due to pharmacological  action of the drug . 
Type B is a idiosyncratic reaction.  
Type C  is due to chronic effects. 
Type D is a delayed reaction.  
Type E is a drug interactions.  
Carbamazepine: 
 MECHANISM OF ACTION 
o Blocks voltage-activated Na channels 
o Reduces polysynaptic responses 
o Blocks post-tetanic potentiation 
o Depresses thalamic potentials 
o Depresses bulbar and polysynaptic reflexes. 
 ADVERSE EFFECTS 
o Most Common Adverse Events in Clinical Trials 
 Tremor 
 Rash 
 Sedation 
 Ataxia 
 Nausea 
 Diplopia 
 Weight gain 
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Oxcarbazepine: 
o Oxcarbazepine blocks sodium-dependent action potentials 
on the basis of voltage- and use-dependent limitation of 
action potential firing (indirect effect). 
o Monohydroxy derivative (MHD) reduces glutamatergic 
synaptic transmission and high-voltage N-type Ca
2+
 currents 
ADVERSE EFFECTS 
In general, the most frequently reported side effects of 
oxcarbazepine include fatigue, headache, dizziness, somnolence, ataxia, 
nausea/vomiting, and diplopia. Other frequently reported adverse effects 
included nausea, rash, abnormal thinking, and acne. Oxcarbazepine and 
VPA were equally well tolerated in monotherapy; the adverse effects of 
oxcarbazepine were similar to that previously observed. Significant 
hyponatremia and Stevens-Johnson syndrome has been reported with 
oxcarbazepine. 
Phenobarbital, Primidone: 
 MECHANISM OF ACTION 
o Primidone metabolized to phenobarbital 
o Enhance Î³-aminobutyric acid (GABA) receptor-mediated 
postsynaptic chloride currents 
o Attenuates presynaptic calcium-dependent potentials. 
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 ADVERSE EFFECTS 
o Most Common Adverse Events in Clinical Trials 
 Sedation 
 Rash 
 Cognitive dysfunction 
 Hyperactivity 
 Ataxia 
o Idiosyncratic reactions. 
 Phenytoin 
 MECHANISM OF ACTION 
o Blocks voltage-activated Na channels 
 ADVERSE EFFECTS 
o The Five Most Common Adverse Events in Clinical Trials. 
Nystagmus, ataxia, slurred speech, decreased coordination, 
and mental confusion 
o Differences in Adverse Effects Profiles in Non“Epilepsy 
Trials versus Epilepsy Trials. None systematically studied 
o Idiosyncratic 
 Others 
 Gingival hyperplasia 
 Lymphadenopathy 
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 Sensory peripheral neuropathy 
 Osteomalacia 
 Topiramate 
 MECHANISM OF ACTION 
o Blocks voltage-activated Na channels 
o Blocks AMPA/kainate type of glutamate receptor 
o Enhances Î³-aminobutyric acid (GABA)“mediated chloride 
flux 
o Reduces amplitude of high-amplitude calcium currents 
o Activates potassium conductance 
o Carbonic anhydrase inhibitor 
 ADVERSE EFFECTS 
o Five Most Common Adverse Events in Clinical Trials 
 At 200- to 400-mg/day dosage as adjunctive therapy, 
the five most common adverse effects were 
somnolence, dizziness, ataxia, nervousness, and 
fatigue. 
      Valproic Acid 
 MECHANISM OF ACTION 
o Blocks voltage-activated Na channels 
o Activates calcium dependant potassium conductance 
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 ADVERSE EFFECTS 
o The five most common adverse effects in clinical trials 
 Nausea, somnolence, tremor, dizziness, asthenia 
o The three most common adverse effects that caused 
discontinuations in clinical trials (epilepsy) 
 Not stated 
o Differences in adverse effect profiles in non“epilepsy trials 
versus epilepsy trials 
 Tremor was less likely to be reported in mania and 
headache trials than in epilepsy trials. 
o Idiosyncratic 
 Rash Rate. 6% rate in clinical trials 
 Serious Rash Rate. Not noted 
 Hepatic Dysfunction Rate. Rate not stated, but cases 
of serious hepatic dysfunction have been reported, 
most within first 6 months of therapy. The highest risk 
groups for hepatic failure are children younger than 2 
years, those receiving multiple AEDs, or those with 
congenital metabolic disorders. 
 Renal Stones. Not noted 
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 Hematologic Dysfunction Rate. Thrombocytopenia in 
up to 27% 
 Pancreatitis. Rate 0.8% in clinical trials; may be rapid 
and fatal 
 Hyperammonemia. More likely to be asymptomatic 
Zonisamide 
 MECHANISM OF ACTION 
o Blocks repetitive firing of voltage-sensitive sodium channels 
o Reduces voltage-sensitive T-type (transient inward) calcium 
channels; it does not affect the L-type calcium channels 
o Has weak activity in inhibiting carbonic anhydrase 
 ADVERSE EFFECTS 
o Tolerability was formally assessed in three major add-on 
trials. The most frequently reported adverse events (10% of 
patients) were fatigue, dizziness, somnolence, anorexia, 
abnormal thinking, and ataxia Idiosyncratic.             
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MATERIALS & METHODS 
SETTINGS: Patients attending epilepsy clinic in neurology department, 
Madras Medical College and Rajiv Gandhi Government general hospital 
Chennai - 600 003. 
ETHICAL APPROVAL: 
Obtained  
STUDY DESIGN: 
A cross sectional study design was chosen. 
PERIOD OF STUDY: 
          JAN 2012 to DEC 2012 
SAMPLE SIZE 
 Cases: 100, Controls: 100 . 
INCLUSION CRITERIA: 
All epilepsy patient receiving AED monotherapy for more than 2 
years.  
Hundred healthy volunteers included as control.  
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EXCLUSION CRITERIA: 
Patients with Epilepsy with the following conditions were excluded 
from the study 
     1.Patients who discontinued AED for more than 2 weeks. 
2.Malabsorption syndrome 
3.Nephrotic syndrome 
4.Diabetes mellitus 
5.Thyroid disorders 
6.Liver disorders 
7.Intake drugs like 
a. Diuretics 
b. Oral contraceptives 
8.Lipid storage disorders 
STUDY POPULATION: 
Hundred epileptic patients and age and sex matched healthy 
controls were selected for the study from epilepsy clinic and outpatient 
department of Rajiv Government General hospital Chennai, after 
36 
 
thorough history taking and clinical examination and by exclusion 
criteria.  
LABAROTARY MEASUREMENTS 
After ensuring 12 hours overnight fasting, normal diet ( without 
any fat restriction) for previous two weeks, and abstinence from alcohol, 
the blood samples were collected from Epilepsy patients & healthy 
controls. From the blood, serum was separated & stored in refrigerator. 
Then this was used for lipoprotein  and CRP analytical studies. 
Concentration of total cholesterol, HDL-cholesterol, and 
triglycerides were assessed enzymatically with commercially available 
reagents. Concentration of LDL- cholesterol was calculated by use of the 
Friedewald equation for participants who had triglycerides (< 400 mg/dl)    
                                  LDL = TC ─ HDL-c ─ TGL/5. 
Common carotid artery IMT was measured by B-mode ultrasound 
System to assess the extent of atherosclerosis . We  scanned both the left 
and right Common carotid artery, defined as the 1-cm vascular wall 
segment of the carotid artery immediately proximal to the dilation of the 
bifurcation plane An optimal longitudinal image was saved and the IMT 
was analyzed using a computerized image analysis system. 
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The vascular risk marker CRP was measured by latex agglutination 
method. The CRP was determined using a Dimension® RxL clinical 
chemistry analyzer in a serum specimen with CRP FlexTM reagent 
cartridges.  A concentration more than 6 mg/L was defined as elevated 
according to the reference values of our laboratory. 
FINANCIAL SUPPORT: nil. 
CONFLICT OF INTEREST: nil 
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STATISTICAL ANALYSIS 
Statistical analysis was carried out for 200 participants [100 
epilespy patients, 100 controls] after categorizing each variable. Base line 
data was collected from patients Age, sex, AED, dosage duration of 
AED, carotid intima media thickness, Lipid profile, BMI, CRP were 
analyzed.  
The significance of difference in means between two groups were 
analyzed by  student t-test. The correlation between duration of  AED and 
average carotid intima media thickness was calculated by  using the 
Pearson's correlation coefficient method.  
Statistical significance was taken when p value was < 0.05. 
Statistical analysis was carried out using standard formulae. Microsoft 
excel 2007 and SPSS (statistical package for social sciences) version 20 
software was used for data entry and analysis. 
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RESULTS  AND  OBSERVATION 
  In our study , 100 epileptic patients matched with 100 healthy 
controls were studied for cardiovascular risk factors namely lipid profile 
(TC, LDL, HDL,TGL), body mass index (BMI), C-reactive protein 
(CRP) and carotid intima media thickness (CIMT) and the following 
observation were made. Patients with age group ranging from 10 to 90 
years were studied. 
Table : 1 - AGE DISTRIBUTION IN CONTROL AND  STUDY 
GROUP 
AGE IN YEARS CONTROL STUDY 
10 -20 22 22 
21 -30 39 35 
31 -40 21 21 
41 -50 08 09 
51 -60 08 10 
61 -70 01 02 
71 -80 01 0 
81 -90 0 01 
 
        In the control group 22 were in the 10-20 age group,39 were in the 
21-30 age group, 21 were in the 31-40 age group,8 were in the 41-50,51-
60 age groups and 1 were in the 61-70, 71-80 age groups. 
       In the study group 22 were in the 10-20 age group,35 were in the 21-
30 age group, 21 were in the 31-40 age group,9 were in the 41-50, age 
group, 10 were in the 51-60 age group,2 were in the 61-70 age group  and 
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1 were in the 81-90 age groups. More epileptic patients were in the age 
group of 21 to 30 years.  
 
TABLE : 2 - AGE DISTRIBUTION IN CONTROL AND  STUDY 
GROUP 
 
 
 Group N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
Age in 
years 
Control 
100 30.65 13.497 1.350 
 Study 100 31.68 14.466 1.447 
 
The mean age in years in control group were 30.65 and in study 
group were 31.68. 
TABLE:3 - COMPARISION OF MEAN-AGE OF STUDY AND  
CONTROL GROUP 
 
t-TEST  
VALUE df P VALUE 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
      Lower Upper 
Age in 
years 
-.521 198 .603 -1.03 1.978 -4.932 2.872 
 
       Age distribution between control and AED study group is not 
statistically different. 
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TABLE:4  SEX DISTRIBUTION IN CONTROL AND  STUDY 
GROUP 
 
SEX 
Group 
Control Study 
 Number of males 45 47 
 % of male 45% 47% 
Number of female 55 53 
 % of female 55% 53% 
 
In the control group 45 (45%) were male and 55 (55%) were   
female. In the study group 47 (47%) were male and 53 (53%) were 
female. 
Chi Square Tests for sex between control and study 
 Value df 
Asymp. Sig. (2-
sided) p value 
Pearson Chi-Square .081(b) 1 .777 
  
 This study shows females preponderance of patients compared to 
males. But there is no significant difference in sex between control and                 
epileptic groups.                                     
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TABLE 5: DURATION AND DOSAGE OF AEDs IN STUDY 
GROUP 
Antiepileptic drug 
No. of 
patients 
Mean duration 
of AEDs(Years) 
with SD 
Dosage 
Range in 
mg/day 
PHENYTOIN 32 5.09 ±3.59 200-400 
CARBAMAZEPINE 28 8.35 ±4.49 400-1200 
VALPROATE 21 6.43±3.21 400-1600 
PHENOBARBITONE 19 8.37 ±4.03 15-60 
 
 The mean duration of AED therapy in carbamazepine and 
phenobarbitone were higher than valproate and phenytoin groups.     
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FIGURE 1:   SEX DISTRIBUTION IN CONTROL AND  STUDY 
GROUP 
 
Sex
FemaleMale
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u
n
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56
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52
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48
46
44
42
Group
Control
Study
 
 
FIGURE 2:  AGE DISTRIBUTION IN CONTROL AND  STUDY 
GROUP 
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FIGURE 3:COMPARISION OF CRP BETWEEN CONTROL AND 
AED GROUP 
 
 
 
FIGURE:4 NUMBER OF PATIENTS IN AEDs GROUP. 
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EFFECT OF PHENYTOIN ON ATHEROSCLEROSIS RISK 
FACTORS:  
TABLE: 6 COMPARISION OFMEAN BMI VALUES OF 
CONTROL AND PHENYTOIN GROUP 
 
Sub 
Group 
N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t 
Sig. (2-
tailed) p 
value 
BMI 
kg/m
2 
Control 
100 22.747 2.6520 .2652 -5.852 .000 
 Phenytoin 32 26.241 3.7119 .6562 -4.936 .000 
 
 
Table: 7 COMPARISION OF MEAN LIPID LEVELS OF 
CONTROL AND PHENYTOIN GROUP 
Lipids in  
mgs% 
Sub 
Group 
N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t 
Sig. (2-
tailed) p 
value 
TC Control 100 158.77 9.700 .970 .721 .472 
 Phenytoin 32 157.47 5.542 .980 .944 .348 
LDL Control 100 95.88 9.213 .921 -.465 .642 
 Phenytoin 32 96.69 5.905 1.044 -.580 .563 
HDL Control 100 32.38 3.966 .397 -1.801 .074 
 Phenytoin 32 33.75 2.929 .518 -2.100 .039 
TGL Control 100 148.69 17.904 1.790 .148 .883 
 Phenytoin 32 148.16 17.428 3.081 .150 .881 
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TABLE: 8 COMPARISION OF MEANS-IMT VALUES OF 
CONTROL AND PHENYTOIN GROUP 
CCA- 
IMT 
(mm) 
Sub 
Group 
N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t 
Sig. (2-
tailed) p 
value 
IMT- 
Right 
Control 
100 .6175 .07120 .00712 -6.548 .000 
 Phenytoin 32 .7544 .16800 .02970 -4.482 .000 
IMT- Left Control 100 .6254 .07656 .00766 -6.785 .000 
 Phenytoin 32 .7409 .10375 .01834 -5.813 .000 
IMT – 
Average 
Control 
100 .6215 .05114 .00511 -9.550 .000 
 Phenytoin 32 .7477 .09696 .01714 -7.056 .000 
 
This study shows epileptic patients on phenytoin has significantly 
raised BMI and  Average IMT mean values when compared to  Controls.                           
Table: 9 COMPARISION OF MEANS BMI VALUES OF 
CONTROL AND CARBAMZEPINE  GROUP 
 
 
Sub 
Group 
N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t 
Sig. (2-
tailed) p 
value 
BMI 
kg/m
2
 
Control 
100 22.747 2.6520 .2652 -.993 .323 
 Carbamze
pine 
28 23.289 2.1605 .4083 -1.114 .270 
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Table: 10 COMPARISION OF MEANS LIPID LEVELS OF 
CONTROL AND CARBAMZEPINE  GROUP 
 
Lipids in  
mgs% 
Sub Group N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t 
Sig. (2-
tailed) p 
value 
TC Control 100 158.77 9.700 .970 -6.128 .000 
 Carbamzep
ine 
28 173.93 16.720 3.160 -4.586 .000 
LDL Control 100 95.88 9.213 .921 -4.981 .000 
 Carbamzep
ine 
28 107.68 16.171 3.056 -3.697 .001 
HDL Control 100 32.38 3.966 .397 .226 .822 
 Carbamzep
ine 
28 32.18 4.839 .914 .202 .841 
TGL Control 100 148.69 17.904 1.790 -1.509 .134 
 Carbamzep
ine 
28 154.07 11.062 2.090 -1.955 .055 
 
TABLE: 11 COMPARISION OF MEANS IMT VALUES OF 
CONTROL AND CARBAMZEPINE  GROUP 
 
CCA- IMT 
(mm) 
Sub Group N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t 
Sig. (2-
tailed)p 
value 
IMT- Right Control 100 .6175 .07120 .00712 -3.993 .000 
 Carbamzepi
ne 
28 .6914 .12808 .02421 -2.930 .006 
IMT- Left Control 100 .6254 .07656 .00766 -4.955 .000 
 Carbamzepi
ne 
28 .7196 .12426 .02348 -3.816 .001 
IMT - 
Average 
Control 
100 .6215 .05114 .00511 -6.376 .000 
 Carbamzepi
ne 
28 .7055 .09035 .01708 -4.717 .000 
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 This study shows epileptic patients on carbamazepine has 
significantly raised TC, LDL-C and Average IMT mean values  when 
compared to Controls .                      
TABLE: 12 COMPARISION OF MEANS BMI VALUES OF 
CONTROL AND   VALPROATE GROUP 
 
 
Sub 
Group 
N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t 
Sig. (2-
tailed)p 
value 
BMI 
kg/m
2
 
Control 
100 22.747 2.6520 .2652 -2.006 .047 
 Sodium 
Valproate 
21 24.095 3.4379 .7502 -1.694 .103 
 
 
TABLE: 13 COMPARISION OF MEANS LIPID LEVELS OF 
CONTROL AND   VALPROATE GROUP 
 
Lipids in  
mgs% 
Sub Group N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t 
Sig. (2-
tailed)p 
value 
TC Control 100 158.77 9.700 .970 -.018 .986 
 Sodium 
Valproate 
21 158.81 5.980 1.305 -.024 .981 
LDL Control 100 95.88 9.213 .921 -1.185 .238 
 Sodium 
Valproate 
21 98.38 6.305 1.376 -1.510 .139 
HDL Control 100 32.38 3.966 .397 -1.758 .081 
 Sodium 
Valproate 
21 34.00 3.130 .683 -2.051 .048 
TGL Control 100 148.69 17.904 1.790 -1.302 .195 
 Sodium 
Valproate 
21 154.05 12.690 2.769 -1.625 .112 
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TABLE: 14 COMPARISION OF MEAN IMT VALUES OF 
CONTROL AND   VALPROATE GROUP 
 
CCA- IMT 
(mm) 
Sub 
Group 
N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t 
Sig. (2-
tailed)p 
value 
IMT- Right Control 100 .6175 .07120 .00712 -5.203 .000 
 Sodium 
Valproate 
21 .7157 .10815 .02360 -3.984 .001 
IMT- Left Control 100 .6254 .07656 .00766 -3.618 .000 
 Sodium 
Valproate 
21 .6924 .07987 .01743 -3.519 .001 
IMT - Average Control 100 .6215 .05114 .00511 -6.248 .000 
 Sodium 
Valproate 
21 .7040 .07143 .01559 -5.035 .000 
 
This study shows epileptic on sodium valproate has significantly 
raised BMI and Average IMT mean values  when compared to Controls. 
Table: 15 COMPARISION OF MEANS BMI VALUES OF 
CONTROL AND  PHENOBARBITONE GROUP 
           
              
 Sub Group N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t 
Sig. (2-
tailed)p 
value 
BMI 
kg/m
2
 
Control 
100 22.747 2.6520 .2652 1.695 .093 
 Phenobarbitone 19 21.642 2.3253 .5335 1.855 .074 
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TABLE: 16 COMPARISION OF MEAN LIPID LEVES OF 
CONTROL AND  PHENOBARBITONE GROUP 
 
 
Lipids in  
mgs% 
Sub Group N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t 
Sig. (2-
tailed)p 
value 
TC Control 100 158.77 9.700 .970 -5.523 .000 
 Phenobarbito
ne 
19 174.11 16.806 3.856 -3.857 .001 
LDL Control 100 95.88 9.213 .921 -4.212 .000 
 Phenobarbito
ne 
19 107.89 19.430 4.458 -2.640 .016 
HDL Control 100 32.38 3.966 .397 -.821 .413 
 Phenobarbito
ne 
19 33.26 5.801 1.331 -.636 .532 
TGL Control 100 148.69 17.904 1.790 -.573 .567 
 Phenobarbito
ne 
19 151.16 12.619 2.895 -.725 .473 
 Phenobarbito
ne 
19 .7126 .11035 .02531 -3.618 .002 
 
      This study shows epileptic patients on Phenobarbitone has 
significantly raised TC and LDL-C mean values when compared to 
Controls. 
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TABLE: 17 COMPARISION OF MEAN IMT VALUES OF 
CONTROL AND  PHENOBARBITONE GROUP 
 
CCA- IMT 
(mm) 
Sub Group N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t 
Sig. (2-
tailed)p 
value 
IMT- Right Control 100 .6175 .07120 .00712 -4.842 .000 
 Phenobarbit
one 
19 .7126 .11035 .02531 -3.618 .002 
IMT- Left Control 100 .6254 .07656 .00766 -2.154 .033 
 Phenobarbit
one 
19 .6674 .08458 .01940 -2.012 .056 
IMT - 
Average 
Control 
100 .6215 .05114 .00511 -4.802 .000 
 Phenobarbit
one 
19 .6900 .08223 .01886 -3.507 .002 
 
 This  shows  patients on Phenobarbitone has significantly raised 
Average IMT mean values when compared to Controls 
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TABLE: 18  CRP. LEVEL – AN ANALYSIS BETWEEN 
CONTROL AND AED GROUP 
CRP 
mg/l 
PHENYTOIN CARBAMAZEPINE VALPROATE PHENOBARBITONE 
control study controls study controls study control study 
Positive 
>6mg/l 
23 18 23 16 23 6 23 5 
Negative 
<6 mg/l 
77 14 77 12 77 15 77 14 
Positive 
% within 
subgroup 
23% 56.3% 23% 57.1% 23% 28.6% 23% 26.3% 
Negative 
% within 
subgroup 
77% 43.8% 77% 42.9% 77% 71.4% 77% 73.7% 
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TABLE:19 COMPARISION OF CRP BETWEEN CONTROL AND 
AED GROUP 
 
 
Pearson Chi-
Square Value 
df 
Asymp. Sig. 
(2-sided) P 
value 
PHENYTOIN 12.516(b) 1 .000 
CARBAMAZEPINE 12.037(b) 1 .001 
VALPROATE .296(b) 1 .587 
PHENOBARBITONE .098(b 1 .755 
 
CRP significantly positive in phenytoin and carbamazepine groups 
when compared to controls. 
   Table:20 CORRELATION BETWEEN DURATION OF AED 
AND AVERAGE-IMT. 
 PHENYTOI
N 
CARBAMA
ZEPINE 
VALPROA
TE 
PHENOBARBI
TONE 
PEARSON 
CORRELATION 
.446 .115 .405 .597 
P value .011 .56 .068 .007 
 
*  Correlation is significant at the 0.05 level (2-tailed). 
**  Correlation is significant at the 0.01 level (2-tailed). 
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By pearson correlation,Phenytoin and phenobarbitone shows 
significant positive correlation between duration of AED and Average 
IMT. 
After adjusting for age and sex by regression analysis,effect of 
phenytoin on average CCA-IMT does not show significant difference 
where as duration of phenobarbitone therapy has a significant effect on 
CCA-IMT. 
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TABLE : 21 SUMMARY OF OBSERVATIONS: 
risk 
factors 
phenytoin carbamazepine valproate phenobarbitone 
BMI ↑(S) NS ↑(S) NS 
TC NS ↑(S) NS ↑(S) 
LDL-C NS ↑(S) NS ↑(S) 
HDL-C NS NS NS NS 
TGL NS NS NS NS 
CCA-IMT ↑(S) ↑(S) ↑(S) ↑(S) 
CRP ↑(S) ↑(S) ↑NS ↑NS 
Correlation 
between 
duration of 
AEDs and 
average 
CCA-IMT 
Insignifica
nt Positive 
correlation 
Insignificant 
Positive 
correlation 
Insignifican
t Positive 
correlation 
Significant 
Positive 
correlation 
S – Significant 
NS –  Not Significant 
↑  -  Increased 
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DISCUSSION 
Patients with epilepsy have to undergo chronic treatment with 
antiepileptic drugs. Most of these individuals undertake treatment during 
most productive period of their lifetime. It is not only important that their 
epileptic seizures have to be under control but also adverse effects due to 
long term antiepileptic drugs (AED) intake have to be minimal. 
           In this context there have been few studies that have indicated that 
long term AED intake has been associated with increased vascular risk 
factors. A Finnish
28
 study had shown to the contrary that the mortality 
due to cardiovascular risk in patients taking long term AEDs was 
significantly lower. Another Norwegian study
29
 has shown that the risk 
for coronary events in patient with epilepsy versus controls was not 
significantly different. 
           In this background , in our setting a large majority of our patients 
are in the most productive life taking long term AEDs. As our hospital 
provides only old generation AEDs, we found that it is informative to 
study the long term effect of old generation AED’s, on cardiovascular 
risk factors especially as they are in the most productive age of their lives. 
With this consideration we analysed patients taking AED monotherapy 
more than two years with age and sex matched controls. We analysed 
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effect of AED on primary cardiovascular (BMI), C-reactive protein(CRP) 
and carotid intima media thickness (CIMT). risk factors namely lipid 
profile ( TC, LDL, HDL,TGL), body mass index  
           In this analysis we found that patients taking   monotherapy with 
phenobarbitone (PB) and carbamazepine (CBZ) had significantly 
increased total cholesterol, low density lipoprotein cholesterol and 
common carotid artery intima media thickness (CCA-IMT) in comparison 
to age and sex matched controls. In previous studies 
26-31
 Bramswig etal
59
 
has shown similar results in that total cholesterol, low density lipoprotein 
and intima media thickness significantly correlated to carbamazepine 
intake. Also similar studies by Mintzer et al
44
., 2009; Belcastro et al
60
., 
2010; Svalheim et al
61
.,2010, have shown that carbamazepine is 
significantly associated with increased total cholesterol and atherogenic 
(Non HDL) cholesterol. This effect of carbamazepine may be due to 
enzyme inducing effects of the drug. The reason for which have been 
detailed earlier.  
  Very few studies are available regarding phenytoin intake and lipid 
levels. some studies showing nonsignificant elevations in total cholesterol 
and high-density lipoprotein cholesterol (HDL-C)
42,43
 Long term 
phenytoin intake which was significantly associated with increased total 
cholesterol, LDL-C levels in Mintzer et al
44
, was not significant in our 
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study. With patients on chronic intake of phenytoin in our study though 
the levels of LDL-C was elevated the difference in elevation was not 
statistically significant.  
The reason for the same could be due to lower average dose 
prescribed in our patients compared to previous studies in western 
population. 
         As our’s is a developing country compared to western country, a 
significantly large number of patients are on phenobarbitone  
monotherapy. We found in this group the levels of total cholesterol, LDL-
C   are significantly elevated which is in comparison to previous western 
data.
33-37,45
This effect of phenobarbitone could be explained due to its 
enzyme inducing effects. This finding is of great importance as 
phenobarbitone is slowly regaining its importance in patients with 
epilepsy in developing countries as a monotherapy, primarily due to its 
cost factors.
62
  
           Chronic valproate intake is not associated with significant 
elevation in   total cholesterol, low density lipoprotein and triglyceride in 
children and adults.
34,36,37,43
 The studies citated earlier have hypothesized 
based on animal models, that non ezyme inducing effect of valproate 
could be the reason for the same. In our also we found that valproate 
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intake was not significantly associated with total cholesterol, low density 
lipoprotein cholesterol elevations. 
 All the drugs in this study was associated with significant increase 
in common carotid artery intima media thickness (CCA-IMT)  similar to 
Schwaninger et al.
56
 The reason could be due to increase in lipid levels in 
enzyme inducing  drugs. 
 However in valproate the same could not be explained as lipid 
levels were not significantly elevated. Previous studies have also shown 
similar results. 
          Chuang HY et al.
63
  have shown positive correlation of vascular 
risk factors with  duration of AED in the CBZ,PH and VPA treatment 
groups but in our study, in patients who was on  Valproate , phenytoin 
and carbamazepine  the duration of therapy was not significantly 
associated with increased common carotid artery intima media thickness 
(CCA IMT). The reason for this could be due to different mechanism of 
action of each drug. In the case of valproate as discussed earlier there was 
no significant elevation in total cholesterol, low density lipoprotein which 
could be the cause for no significant increase in common carotid artery 
intima media thickness (CCA-IMT) The reason that, phenytoin and 
carbamazepine duration of therapy not contributing  to common carotid 
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artery intima media thickness (CCA-IMT), could be due to lower doses of 
drugs probably given in our population. 
CRP has been found to be an independent risk factor for vascular 
disease.
49-51
 However whether CRP is a direct cause for the process or 
whether it is an surrogate marker for the other pathological process is not 
clear. The role of  AEDs in relation to CRP level is not well established . 
An article by Mintzer et al
44
 has found that the level of CRP was reduced 
when patients were changed from enzyme inducing  to non enzyme 
inducing agents.  
In our study also we found out that patient on carbamazepine and 
phenytoin had significantly elevated levels of CRP. While patients on 
Valproate did not have significantly elevated levels of CRP. However  
Phenobarbitone  which is an enzyme inducer did not affect levels of CRP.  
Though these observations correlate with studies
52
 done earlier the reason 
for CRP levels not being elevated in patients on Phenobarbitone therapy 
is not clear.  
Long term intake with Valproate therapy has been associated with 
increased body mass index which is one of the criteria for metabolic 
syndrome.Metabolic syndrome is an independent risk factor for 
cardiovascular disease. Carbamazepine has also been found to marginally 
increase body mass index.
66
In our study we found the Valproate and 
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Phenytoin were associated  with increased body mass index. While 
Carbamazepine and Phenobarbitone therapy did not affect the same. 
Though Valproate effect on body mass index is well established the role 
of other AEDs on body mass index is not well known. Perhaps we need a 
large sample size to study the effect of AED monotherapy on BMI.The 
limitation of this study is that the quantification of CRP using various 
dilutions was not done. The sample size was likely to be insufficient  and 
hence a type II error in these results cannot be ruled out. 
From the above observation it is clear that AEDs have a variable 
effect on each of the vascular risk factors, probably due to different 
mechanism. This effect has to be studied on a larger sample size to assess 
the long term effect of anti epileptic drugs on vascular risk factors 
especially in those requiring long term AEDs and in elderly patients.  
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CONCLUSION 
 
The following conclusions were observed from our study.  
 
1. Epileptic patients on carbamazepine and phenobarbitone had 
significantly elevated levels of serum total cholesterol, LDL-
cholesterol and CRP. HDL-cholesterol level, Triglyceride and body 
mass index were not significantly altered in these groups.  
2. Patients on phenytoin and sodium valproate had significantly 
elevated body mass index. There was no significant effect on lipid 
levels and CRP in this group.  
3. All the antiepileptic drugs in this study significantly increased the 
common carotid artery intima media thickness.  
4. It is observed that there is significant positive correlation between 
duration of phenobarbitone therapy and average common carotid 
artery intima media thickness which was not noted with 
carbamazepine, phenytoin and sodium valproate. 
This study of antiepileptic drugs on vascular risk factors will have 
a bearing on the selection of AEDs in refractory epileptic patients and 
elderly patients. Hence a lonterm study has to be conducted in a large 
sample of epileptic patients to assess the effects of AEDs on vascular risk 
factors especially in those requiring long term AEDs and in elderly 
patients. 
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PHENYTOIN
S.NO. NAME
AGE 
(years) SEX MIN NO
DURATIO
N
DOSAGE 
mg
seizure 
type Etioloy
BMI 
kg/m2
TC 
mg%
LDL  
mg%
HDL  
mg%
TGL  
mg% CRP mg/L
IMT(R)m
mIMT(L)
mm
IMT 
(LT)
1 Veerammal 40 F 16615/11 2 years 300 GTCS Idiopathic 23.3 152 106 30 139 NEGATIVE 0.53 0.83
2 Yasmin 28 F 14842/11 2 300  GTCS Idiopathic 24.4 155 99 32 119 NEGATIVE 0.56 0.86
3 Kuppu 38 F 14834/11 2 200 GTCS Idiopathic 20.2 150 95 29 130 NEGATIVE 0.65 0.76
4 Arumugam 70 M 83467/10 3 300 GTCS Idiopathic 20.9 166 92 29 159 >6 1.03 0.78
5 Ramani 34 F 26582/08 9 300 GTCS Idiopathic 21.6 157 89 34 145 >6 0.98 0.6
6 Chandran 53 M 12428/03 4 200 GTCS Idiopathic 23.9 162 90 35 141 NEGATIVE 0.62 0.82
7 Subbulaxmi 29 F 4494/10 2 200 GTCS Idiopathic 23.2 170 88 33 147 NEGATIVE 0.54 0.64
8 Annapoorna 40 F 1332/10 8 200 GTCS Idiopathic 23.4 154 99 31 125 >6 1.04 0.71
9 subbulaxmi 29 F 4494/10 5 300 GTCS Idiopathic 25.5 159 93 39 157 >6 0.85 0.63
10 velmurugan 26 M 32939/07 2 200 GTCS Idiopathic 26 164 89 30 163 NEGATIVE 0.51 0.8
11 vembu 28 F 3206/05 7 300 GTCS symptomatic 29.4 151 92 32 179 >6 0.77 0.61
12 saravanan 30 M 34841/08 4 300 GTCS Idiopathic 29.1 154 100 37 169 >6 0.73 0.66
13 subash 16 M 2653/10 3 200 GTCS Idiopathic 29.9 150 102 32 125 NEGATIVE 0.6 0.88
14 CHARLES 37 M 16533/09 15 200 GTCS Symptomatic 32.1 155 107 30 153 >6 0.99 0.7
15 Kanniga 42 F 21151/02 10 300 GTCS Idiopathic 31.1 157 103 37 169 NEGATIVE 0.81 0.66
16 Parameshwaran 55 M 30749/98 15 300 GTCS symptomatic 28.4 159 96 36 128 >6 0.89 0.78
17 Ganesan 31 M 21541/03 9 300 GTCS Idiopathic 30.3 150 89 34 179 NEGATIVE 0.73 0.74
18 Leelavathy 23 F 19181/10 2 200 CPS Idiopathic 27.6 152 91 32 143 NEGATIVE 0.58 0.62
19 Rajesh 21 M 791/10 2 200 GTCS Idiopathic 26.7 151 94 35 149 NEGATIVE 0.64 0.8
20 Usha 49 F 14152/08 4 300 Partial Idiopathic 25.5 155 96 37 160 NEGATIVE 0.55 0.6
21 kumaravel 30 M 33955/08 4 300 GTCS Idiopathic 26 157 98 37 134 >6 1.01 0.76
22 Mythili 27 F 30560/10 2 200 GTCS Idiopathic 24.4 159 104 34 124 >6 0.93 0.72
23 JAYALAXMI 61 F 21848/09 10 300 GTCS Idiopathic 22.8 161 108 31 126 >6 0.91 0.92
24 Bagyalakshmi 25 F 21127/08 4 200 GTCS Symptomatic 22.7 160 100 35 164 >6 0.84 0.9
25 Akbar 24 M 453/05 7 400 GTCS Idiopathic 20.4 161 106 38 140 >6 0.86 0.95
26 Balachandar 23 M 12862/02 4 300 GTCS Idiopathic 21 151 96 37 146 NEGATIVE 0.67 0.77
27 Barani 82 F 27036/10 2 200 GTCS Idiopathic 29.3 163 94 35 142 >6 0.68 0.84
28 govindasamy 44 M 12047/08 4 300 GTCS Idiopathic 31.6 154 89 30 130 >6 0.59 0.58
29 pachaiyappan 28 M 23454/08 5 200 GTCS Idiopathic 32.3 164 92 33 152 >6 0.97 0.6
30 SATHYA 24 F 1361/07 4 300 GTCS Idiopathic 30.7 157 97 32 168 >6 0.75 0.79
31 David 38 M 21621/09 3 200 GTCS Idiopathic 28.9 169 98 36 174 >6 0.72 0.67
32 suresh 35 M 29431/08 4 200 GTCS Idiopathic 27.1 160 102 38 162 NEGATIVE 0.61 0.73
33 Shobana 27 F 53041/02 10 400 GTCS Idiopathic 23 154 89 30 154 NEGATIVE 0.57 0.53
34 Karthika 17 F 52143/02 10 400 Partial symptomatic 22.2 168 97 36 155 >6 0.63 0.59
35 BALAJI 29 M 2201/94 8 400 GTCS Idiopathic 27.4 188 122 32 159 >6 0.87 0.65
36 KANNAGI 24 F 2816/07 7 1200 GTCS Idiopathic 19.1 196 130 30 160 >6 0.83 0.91
37 AMSAVALLI 22 F 5382/10 3 400 Partial symptomatic 18.8 142 83 22 148 NEGATIVE 0.56 0.84
38 Karthik 52 M 21193/06 6 400 GTCS symptomatic 24.4 172 104 34 159 NEGATIVE 0.48 0.82
39 VASANTHA 50 F 14703/04 8 400 GTCS Idiopathic 22.4 182 114 32 150 NEGATIVE 0.59 0.74
40 SRINIVASAN 38 M 4275/10 2 400 GTCS Idiopathic 25.1 174 106 37 154 NEGATIVE 0.65 0.72
41 RAJAVENI 38 F 27074/97 15 800 Partial Idiopathic 20.9 176 106 36 137 >6 0.89 0.51
42 Parameshwaran 40 M 5120/94 10 600 GTCS Idiopathic 21.5 182 122 26 144 >6 0.78 0.83
43 VIMALA 21 F 15232/96 10 600 CPS Idiopathic 25.7 170 107 28 141 >6 0.74 0.92
44 RAVI 57 M 18694/94 18 600 GTCS Idiopathic 24.2 192 126 32 160 >6 0.71 0.66
45
SOUNDARAJA
N 60 M 36817/06 6 600 CPS Idiopathic 22.8 152 91 30 155 NEGATIVE 0.61 0.69
46 SRILATHA 43 F 16881/04 8 600 GTCS Idiopathic 22.2 184 129 26 141 >6 0.83 0.77
47 REVATHI 25 F 170871/98 12 400 Partial symptomatic 24.4 182 111 37 132 >6 0.88 0.79
48 SASIKALA 28 F 4201/98 14 400 GTCS Idiopathic 23.6 184 109 43 159 >6 0.76 0.53
49 ABDUL VASI 23 M 5062/09 3 400 CPS Idiopathic 22.6 174 106 33 133 NEGATIVE 0.49 0.57
50 YASODHA 32 F 26299/05 8 800 GTCS Idiopathic 24.4 146 74 40 159 >6 0.82 0.64
51 KANNIYAPPAN 54 M 21517/01 11 600 CPS Idiopathic 24.1 208 139 34 165 >6 0.75 0.68
52 MURUAN 53 M 33720/07 5 400 GTCS Idiopathic 26.6 168 106 30 157 >6 0.71 0.82
53 ASHWINI 14 F 23643/07 5 400 GTCS Idiopathic 26.7 154 89 30 172 >6 0.7 0.86
54 JAYALAXMI 30 F 83542/07 5 400 GTCS Idiopathic 20.8 168 96 36 178 NEGATIVE 0.57 0.74
55
DHANALAKSH
MI 40 F 124662/90 10 600 Partial Idiopathic 21.6 188 123 32 164 NEGATIVE 0.52 0.53
56 BAKIYAM 37 F 3238/09 3 400 GTCS Idiopathic 26.5 196 129 30 154 NEGATIVE 0.64 0.64
57 SHANTI 36 F 6577/90 20 600 GTCS Idiopathic 22.2 142 84 22 158 >6 0.88 0.67
58 ANITHA 14 F 31386/10 3 400 Partial Idiopathic 23.6 172 103 34 164 >6 0.74 0.76
59 ABDUL WAHID 30 M 32326/05 7 400 GTCS Idiopathic 22.9 182 115 32 142 NEGATIVE 0.66 0.9
60 ABDUL RASAK 29 M 5127/05 7 400 GTCS Idiopathic 22.4 174 105 37 160 NEGATIVE 0.5 0.84
CARBAMAZEPINE
61 SARANYAN 14 M 3177/07 6 500 GTCS Idiopathic 29.5 162 92 34 156 NEGATIVE 0.65 0.62
62 SATHISH 16 M 37200/09 3 400 GTCS Idiopathic 19.2 165 104 29 134 NEGATIVE 0.72 0.68
63 SANGEETHA 14 F 3729/04 8 600 GTCS Idiopathic 20.8 153 89 38 162 NEGATIVE 0.8 0.58
64 PENCILLAMA 60 F 34837/08 10 600 GTCS symptomatic 24.3 151 90 33 167 >6 0.87 0.82
65 JAQUALINE 20 F 25443/10 2 400 GTCS Idiopathic 22.8 160 106 32 172 NEGATIVE 0.57 0.75
66 SARAVANAN 16 M 13265/10 3 400 GTCS Idiopathic 26.8 166 107 29 164 >6 0.88 0.73
67 SWATHI 25 F 12044/02 4 600 GTCS symptomatic 22.7 169 97 33 167 NEGATIVE 0.61 0.6
68
MOHANASUND
ARI 29 F 32132/11 2 600 GTCS Idiopathic 20.1 154 99 39 153 NEGATIVE 0.69 0.83
69 ABILASH 13 M 25658/10 2 400 GTCS Idiopathic 19.2 152 102 35 152 NEGATIVE 0.56 0.62
70
BALASUBRAM
ANIAM 53 M 16239/98 12 1600 GTCS Idiopathic 26.5 150 107 34 159 >6 0.85 0.7
71 ARUN KUMAR 15 M 25621/03 9 400 GTCS Idiopathic 28.8 159 104 33 130 NEGATIVE 0.67 0.74
72 Arumugam 12 M 8645/06 6 400 GTCS Idiopathic 27.9 160 93 36 154 NEGATIVE 0.77 0.66
73 ARULRAJ 38 M 36087/07 11 400 GTCS Idiopathic 27.4 161 91 38 136 >6 0.84 0.58
74 JENNIE 24 F 25446/03 4 400 GTCS Idiopathic 23.6 163 90 32 155 NEGATIVE 0.63 0.67
75 ANSAR BASHA 30 M 36943/07 5 600 GTCS Idiopathic 20 162 94 29 161 NEGATIVE 0.59 0.63
76 ANNADURAI 32 M 23235/03 8 600 GTCS Idiopathic 19.1 165 101 39 167 >6 0.83 0.75
77 ANAND 44 M 6750/05 10 600 GTCS Idiopathic 23.3 168 104 37 155 NEGATIVE 0.71 0.79
78 BASKAR 34 M 3586/99 5 400 GTCS Idiopathic 24.1 154 107 36 165 NEGATIVE 0.64 0.81
79 ANSAR BEE 24 F 1849/98 10 600
MYOCLO
NUS Idiopathic 25.2 152 96 33 142 NEGATIVE 0.71 0.6
80
ANTHONY 
AMMAL 28 F 37277/08 9 800 GTCS Idiopathic 26.1 153 94 31 130 >6 0.85 0.7
81 ARUN 17 M 20672/98 6 400 Partial Idiopathic 28.6 156 99 34 154 NEGATIVE 0.59 0.68
82 BABY 58 F 6301/80 11 30 GTCS Idiopathic 18.7 176 107 36 142 >6 0.86 0.72
83 BALAKUMAR 35 M 1310/03 8 60 GTCS Idiopathic 24.6 182 121 26 154 NEGATIVE 0.65 0.59
84
CHANDRAKAL
A 12 F 6059/03 8 60 GTCS Idiopathic 24.2 170 108 28 160 NEGATIVE 0.55 0.54
85 MANIKANDAN 13 M 22422/09 20 30 GTCS Idiopathic 22.1 192 125 32 162 >6 0.84 0.78
86 BHAVANI 21 F 5018/01 9 60 GTCS Idiopathic 27 152 92 30 150 NEGATIVE 0.53 0.69
87 REKHA 43 F 10308/90 4 30 Partial Idiopathic 20.2 184 128 26 146 NEGATIVE 0.62 0.8
88 BHASKARAN 28 M 12668/98 4 30 GTCS Idiopathic 20.8 182 112 37 144 NEGATIVE 0.67 0.61
SODIUM VALPROATE
PHENOBARBITONE
89 ELIYAS 17 M 36550/99 11 60 GTCS Idiopathic 19.4 184 108 43 144 NEGATIVE 0.72 0.56
90 LATHA 33 F 3775/06 7 30 GTCS Idiopathic 22.8 174 107 33 148 NEGATIVE 0.77 0.66
91 KISHORE 18 M 12086/03 9 30 GTCS symptomatic 20.8 146 73 40 134 >6 0.82 0.76
92 BHAVANI 13 F 27638/08 12 60 GTCS Idiopathic 18.6 208 140 34 150 >6 0.87 0.74
93 KAVIRAMAN 10 M 28252/06 6 45 GTCS Idiopathic 18.4 168 105 30 162 NEGATIVE 0.54 0.68
94 BHASKAR 26 M 3789/89 4 60 GTCS Idiopathic 19.4 148 71 44 164 NEGATIVE 0.63 0.57
95 HEMALATHA 13 F 17805/07 5 60 GTCS symptomatic 21.2 184 120 28 160 NEGATIVE 0.69 0.7
96 HAZEERA 13 F 16137/02 10 30 GTCS Idiopathic 21.9 152 89 26 182 NEGATIVE 0.74 0.78
97 BHANUMATHI 45 F 12629/95 10 60 GTCS Idiopathic 24.4 164 87 42 154 >6 0.85 0.71
98
DHANALAKSH
MI 43 F 9145/89 8 60 GTCS Idiopathic 21.5 198 141 30 132 NEGATIVE 0.78 0.6
99 KAIRUN NISHA 33 F 6637/99 11 15 GTCS Idiopathic 22.8 170 109 35 130 NEGATIVE 0.76 0.64
100
DHANALAKSH
MI 13 F 24734/11 2 60 GTCS Idiopathic 22.4 174 107 32 154 NEGATIVE 0.65 0.55
S.NO. NAME AGE SEX BMI kg/m2 TC mg%
LDL  
mg%
HDL  
mg%
TGL  
mg% CRP mg/L IMT®mm IMT(L)mm
1 Ranjith M 39 19.4 162 104 30 139 NEGATIVE 0.54 0.52
2 Janaki F 27 20.6 154 98 32 119 NEGATIVE 0.57 0.61
3 Saroja F 36 20.2 146 90 30 130 NEGATIVE 0.6 0.66
4 Prema F 68 18.8 176 110 34 159 NEGATIVE 0.65 0.64
5 saran M 32 19.9 163 98 36 145 NEGATIVE 0.7 0.59
6 Ganesh M 55 20.4 160 103 28 141 >6 0.72 0.55
7 Paulraj M 30 26.2 168 105 33 147 >6 0.74 0.61
8 Amuda F a 23.3 162 107 30 125 NEGATIVE 0.5 0.66
9 Allice F 29 25.1 145 78 35 157 NEGATIVE 0.62 0.68
10 Javid M 26 27 152 83 36 163 NEGATIVE 0.64 0.57
11 Vasantha F 29 18.7 172 100 36 179 NEGATIVE 0.55 0.53
12 kannan M 30 27.2 172 102 36 169 NEGATIVE 0.73 0.68
13 Kamala F 17 18.6 152 99 28 125 NEGATIVE 0.58 0.61
14 Ponnamal F 37 24.3 170 107 32 153 >6 0.71 0.52
15 Munuswamy M 40 19 152 84 34 169 NEGATIVE 0.5 0.51
16 Jayalakshmi F 54 22.4 158 97 35 128 NEGATIVE 0.61 0.57
17 Kalavathi F 32 21.6 160 94 30 179 NEGATIVE 0.68 0.63
18 Komathi F 24 22.8 144 91 24 143 NEGATIVE 0.56 0.68
19 subramani M 22 20.2 166 100 36 149 NEGATIVE 0.53 0.59
20 Geethabai F 48 19.4 142 84 26 160 NEGATIVE 0.59 0.64
21 Javeena F 31 23.7 162 105 30 134 >6 0.75 0.78
22 kuppan M 27 24.8 154 97 32 124 >6 0.51 0.72
23 Chokamal F 60 19.9 146 90 30 126 NEGATIVE 0.57 0.73
24 Sangeetha F 24 19 176 109 34 164 NEGATIVE 0.53 0.56
25 moses M 24 22.9 163 99 36 140 >6 0.72 0.75
26 Rajeswari F 23 23.4 160 102 28 146 NEGATIVE 0.64 0.52
27 Parimala F 80 24.6 168 106 33 142 NEGATIVE 0.59 0.6
28 kaliammal F 42 19.8 162 106 30 130 NEGATIVE 0.66 0.7
29 kumar M 28 20.7 145 79 35 152 NEGATIVE 0.53 0.73
30 sundar M 28 25.2 152 82 36 168 NEGATIVE 0.72 0.56
31 Saraswathi F 24 18.9 172 101 36 174 >6 0.67 0.62
32 shankar M 36 23.9 172 101 36 174 NEGATIVE 0.61 0.58
33 vijay M 34 23.7 152 100 28 120 NEGATIVE 0.7 0.54
34 mohan M 26 22.9 170 106 32 158 >6 0.72 0.56
35 Gandhimathi F 18 25.7 152 85 34 164 NEGATIVE 0.6 0.59
36 Selvanayaki F 28 26.2 158 96 35 132 NEGATIVE 0.54 0.52
37 Kasthuri F 24 21.6 160 95 30 174 NEGATIVE 0.56 0.6
38 Sarasu F 20 21.3 144 90 24 148 NEGATIVE 0.5 0.55
39 Gurunath M 50 19.5 166 101 36 144 NEGATIVE 0.51 0.7
40 Priya F 50 22.1 142 83 26 165 NEGATIVE 0.58 0.77
41 Rajesh M 36 26.7 142 78 36 138 >6 0.52 0.76
42 Anjali F 36 21 155 91 35 142 >6 0.56 0.77
43 Shankar M 40 22.7 165 89 40 176 0.65 0.58
44 Krishnan M 21 23.4 148 90 32 128 >6 0.72 0.65
45 Vimal M 56 23.7 164 105 30 143 NEGATIVE 0.7 0.76
46 Thilaga F 55 25.2 170 109 32 143 NEGATIVE 0.62 0.74
47 Jayaselan M 42 27.6 152 88 28 118 NEGATIVE 0.56 0.69
48 Das M 26 25.3 162 85 42 173 NEGATIVE 0.53 0.53
49 Elcy F 28 18.9 162 92 35 174 NEGATIVE 0.67 0.61
50 Gunalakshmi F 23 20.4 160 107 24 142 NEGATIVE 0.62 0.7
51 Munuswamy M 20 23.7 166 84 30 138 NEGATIVE 0.56 0.63
52 Siva M 30 26.4 158 90 33 164 >6 0.69 0.64
53 Rajinisha F 52 21.3 168 99 32 126 >6 0.74 0.65
54 jagan M 50 23 172 102 30 119 NEGATIVE 0.7 0.68
55 Indra F 14 22.1 142 91 36 130 NEGATIVE 0.57 0.71
56 Malliga F 30 24.3 164 85 34 140 NEGATIVE 0.63 0.54
57 Gowri F 31 25.1 160 109 36 159 NEGATIVE 0.66 0.73
58 Rada F 37 25.7 170 106 28 146 NEGATIVE 0.6 0.76
59 Nagalakshmi F 35 27.2 166 101 32 145 NEGATIVE 0.57 0.63
60 Venila F 14 19.4 154 105 30 142 NEGATIVE 0.6 0.66
61 Kanchana F 28 18.9 145 105 36 141 >6 0.73 0.54
62 Rajina bee F 29 22.8 176 107 35 130 NEGATIVE 0.65 0.52
63 Ramanan M 14 24.6 170 100 36 147 NEGATIVE 0.61 0.57
64 Uma F 18 26.9 163 90 24 152 NEGATIVE 0.52 0.56
65 Saroja F 15 24.3 162 101 32 125 NEGATIVE 0.64 0.54
66 Saveetha F 55 19.8 154 104 26 168 NEGATIVE 0.64 0.66
67 Narasiman M 22 26.4 160 98 35 157 NEGATIVE 0.62 0.6
68 Valarmathi F 14 19.8 142 84 35 174 NEGATIVE 0.54 0.51
69 Padma F 23 23.3 176 90 24 163 NEGATIVE 0.72 0.74
70 Rosemary F 26 23 164 107 32 174 NEGATIVE 0.69 0.65
71 Magesh M 13 22.4 152 106 26 179 NEGATIVE 0.58 0.6
72 Guru M 38 20.6 148 101 32 120 NEGATIVE 0.56 0.67
73 suresh M 15 25.9 152 82 32 169 NEGATIVE 0.52 0.55
74 Saraswathi F 13 27.1 160 110 42 158 NEGATIVE 0.63 0.64
75 Younis M 36 23.4 152 100 34 125 NEGATIVE 0.66 0.61
76 mani M 24 22.3 172 94 24 164 >6 0.68 0.58
77 Suguna F 30 24.6 170 107 28 153 >6 0.73 0.72
78 Ragavan M 30 20.6 152 109 28 132 >6 0.55 0.75
79 Salima F 42 23.3 162 106 33 169 0.74 0.54
80 Parvathy F 30 26.9 172 85 35 128 >6 0.64 0.52
81 Kousalya F 26 19.6 144 78 34 174 >6 0.59 0.72
82 Mohan M 29 22.8 154 89 36 179 NEGATIVE 0.55 0.74
83 Antony M 16 24.8 160 78 30 148 NEGATIVE 0.51 0.62
84 Venkat M 56 25.7 172 85 28 143 NEGATIVE 0.63 0.68
85 Chinnaponu F 35 26.1 146 83 36 144 NEGATIVE 0.57 0.54
86 Jothy F 22 20.9 170 92 34 149 NEGATIVE 0.55 0.64
87 Valli F 12 18.7 165 99 36 165 NEGATIVE 0.52 0.73
88 Geetha F 13 19.6 162 88 30 160 NEGATIVE 0.61 0.65
89 Shantha F 22 22.7 158 91 40 134 >6 0.6 0.69
90 Murugan M 40 26.2 162 83 30 138 NEGATIVE 0.58 0.55
91 Mayavathi F 21 27.1 152 106 34 124 NEGATIVE 0.59 0.62
92 Meerajothi F 16 20.4 162 79 36 142 NEGATIVE 0.54 0.6
93 Jayaram M 32 23.3 146 90 30 143 NEGATIVE 0.75 0.52
94 Raja M 18 19.3 144 96 30 176 NEGATIVE 0.71 0.57
95 shanthakumar M 13 26.6 142 98 35 118 >6 0.69 0.58
96 arokiaswamy M 12 18.8 155 92 36 128 NEGATIVE 0.67 0.52
97 Hemath M 28 20.9 162 97 36 173 NEGATIVE 0.65 0.56
98 senthil M 12 21.6 168 107 35 143 NEGATIVE 0.62 0.67
99 muthu M 16 22 145 100 30 174 NEGATIVE 0.61 0.54
100 velu M 45 22.7 152 98 36 142 NEGATIVE 0.56 0.58
